Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Enterprise Value (2016 - 2025)

Amphastar Pharmaceuticals has reported Enterprise Value over the past 13 years, most recently at -$172.4 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$172.4 million for Q4 2025, up 22.23% from a year ago — trailing twelve months through Dec 2025 was -$172.4 million (up 22.23% YoY), and the annual figure for FY2025 was -$172.4 million, up 22.23%.
  • Enterprise Value for Q4 2025 was -$172.4 million at Amphastar Pharmaceuticals, up from -$276.2 million in the prior quarter.
  • Over the last five years, Enterprise Value for AMPH hit a ceiling of -$56.4 million in Q1 2021 and a floor of -$289.6 million in Q1 2024.
  • Median Enterprise Value over the past 5 years was -$183.7 million (2022), compared with a mean of -$181.0 million.
  • Biggest five-year swings in Enterprise Value: plummeted 400.17% in 2021 and later skyrocketed 36.12% in 2025.
  • Amphastar Pharmaceuticals' Enterprise Value stood at -$126.6 million in 2021, then crashed by 38.88% to -$175.8 million in 2022, then rose by 17.77% to -$144.5 million in 2023, then tumbled by 53.35% to -$221.6 million in 2024, then increased by 22.23% to -$172.4 million in 2025.
  • The last three reported values for Enterprise Value were -$172.4 million (Q4 2025), -$276.2 million (Q3 2025), and -$187.9 million (Q2 2025) per Business Quant data.